Oncotarget

Corrections:

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

PDF  |  How to cite

Oncotarget. 2019; 10:1344-1344. https://doi.org/10.18632/oncotarget.26685

Metrics: PDF 356 views  |   ?  

Michal Alon1, Rand Arafeh1, Joo Sang Lee2,3, Sanna Madan2,3, Shelly Kalaora1, Adi Nagler1, Tereza Abgarian1, Polina Greenberg1, Eytan Ruppin2,3 and Yardena Samuels1

1 Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel
2 Center for Bioinformatics and Computational Biology, The University of Maryland, College Park, Maryland, USA
3 Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA

Published: February 12, 2019

This article has been corrected: The correct Acknowledgments information is given below:

ACKNOWLEDGMENTS

The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

Original article: Oncotarget. 2018; 9:31264-31277. DOI: https://doi.org/10.18632/oncotarget.25805.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26685